Cargando…
NT-proBNP as predictor factor of cardiotoxicity during trastuzumab treatment in breast cancer patients
BACKGROUND: Trastuzumab is a drug used in HER2-positive breast cancer that increases patient survival. Due to cardiotoxicity is the most important side effect of trastuzumab treatment, cardiac monitoring should be a priority. The purpose of this study is to evaluate plasma NT-proBNP level and major...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7511727/ https://www.ncbi.nlm.nih.gov/pubmed/32977298 http://dx.doi.org/10.1016/j.breast.2020.09.001 |